For TSA treatment, 4 × 10 fibroblasts at passage three were added to 3-cm culture dishes containing DMEM/F-12 plus 10 % FCS supplemented with either 1.0 (treatment) or 0.0 (control) μM of TSA and cultured for 24 h before being trypsinized for SCNT or flowcytometry assessment of epigenetic marks as described elsewhere [ 60].
Trichostatin A (TSA) at 1 μM or equal volumes of 95% ethanol (E) (solvent control for TSA) was then added to the cells treated with 5-Aca-2'-dC, or control cells, which were incubated for another 24 hours before western blot analysis.
For evaluating TSA treatment we probed Western blots of control and TSA-treated extracts of H2B-mRFP/H3-PA-GFP expressing cells with α-mouse anti-GFP (Roche # 11814460001), a α-rabbit H3 acetyl antibody, H3K9Ac and H3K14Ac (all acetylation antibodies from Upstate).
For negative controls, we used empty plates of TSA that were taken to the sampling site during collection.
While we realize that primary hepatocytes would be a better model to evaluate this pathway, we choose the HepG2 cell line as an means to evaluate this phenomenon but allowing for use of the known anti-cancer effects of TSA as a control.
A total of 2,592 genes (3,958 probesets) exhibited at least a two-fold difference compared to controls upon TSA treatment, and of these genes 66% were increased (1,718 genes) and 33% were decreased (874 genes) in expression.
The depth-resolved structural feature vector is extracted from about 70-75 cell nuclei of control and TSA-treated synchronized G1-phase populations of HeLa cells respectively.
Balb/C mice were pre-treated with 0.05 mg of TSA per mouse or a control by intra-peritoneal injections on day 0. Mice were given the same dose of TSA or control each day for days 0 through 3. Mice were give 1×108 pfu/mouse of VVdd-luciferase or luciferase-expressing B18R/tk-deleted vaccinia virus by intravenous injection into the tail vein on day 1 after a 3 hour pre-treatment with TSA.
From GEO, we downloaded 7 microarray data of mouse osteoblastic cells (MC3T3-E1) treated by Trichostatin A (TSA, an HDAC inhibitor), including three replicates of TSA treatment and four replicates of control (GEO: GDS3002).
In TSA case, there were 7 microarray data of mouse osteoblastic cells (MC3T3-E1) treated by Trichostatin A, including three replicates of TSA treatment and four replicates of control (GEO: GDS3002).
Prior to harvesting, adherent cultures of control and TSA-treated cells in DMEM containing 1 or 4.5 mg/ml glucose were washed twice with cold phosphate- buffered saline (PBS) and then lysed with ion-freeH2O for 5 min on ice.
